- Home
- URGN vs AFRI Comparison
URGN vs AFRI Comparison
Compare URGN & AFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- AFRI
- Stock Information
- Founded
- URGN 2004
- AFRI 1943
- Country
- URGN United States
- AFRI Gibraltar
- Employees
- URGN N/A
- AFRI N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- AFRI Packaged Foods
- Sector
- URGN Health Care
- AFRI Consumer Staples
- Exchange
- URGN Nasdaq
- AFRI Nasdaq
- Market Cap
- URGN 181.2M
- AFRI 210.9M
- IPO Year
- URGN 2017
- AFRI N/A
- Fundamental
- Price
- URGN $14.82
- AFRI $7.73
- Analyst Decision
- URGN Strong Buy
- AFRI
- Analyst Count
- URGN 9
- AFRI 0
- Target Price
- URGN $26.81
- AFRI N/A
- AVG Volume (30 Days)
- URGN 5.9M
- AFRI 13.2K
- Earning Date
- URGN 08-12-2025
- AFRI 06-24-2025
- Dividend Yield
- URGN N/A
- AFRI N/A
- EPS Growth
- URGN N/A
- AFRI N/A
- EPS
- URGN N/A
- AFRI N/A
- Revenue
- URGN $91,871,000.00
- AFRI $274,223,000.00
- Revenue This Year
- URGN $36.65
- AFRI N/A
- Revenue Next Year
- URGN $88.35
- AFRI N/A
- P/E Ratio
- URGN N/A
- AFRI N/A
- Revenue Growth
- URGN 8.98
- AFRI N/A
- 52 Week Low
- URGN $3.42
- AFRI $7.53
- 52 Week High
- URGN $18.15
- AFRI $12.00
- Technical
- Relative Strength Index (RSI)
- URGN 73.80
- AFRI 43.96
- Support Level
- URGN $6.92
- AFRI $7.69
- Resistance Level
- URGN $15.22
- AFRI $7.83
- Average True Range (ATR)
- URGN 1.57
- AFRI 0.17
- MACD
- URGN 1.17
- AFRI 0.02
- Stochastic Oscillator
- URGN 96.49
- AFRI 57.78
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About AFRI Forafric Global PLC
Forafric Global PLC is engaged in production and sale of a variety of wheat flours, Semolina and Pasta and Couscous in Morocco and in more than 45 countries. The two main brands in Morocco are MAYMOUNA and TRIA. The company derives majority of its revenue from Soft wheat.